Strike Bio, Inc. Report issue

For profit Phase 1
Founded: Dallas qTX United States (2008)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2012
NCT01505153
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

pbi-shrna ews/fli1 type 1 lpx (1 trial)

pbi-shrna stmn1 lp (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Second Primary (Phase 1)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 1)

Rare Diseases (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2